Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday. The Korea Food and Drug Administration said generic products made by the three local firms have passed a “bioequivalence” test. “The three firms are expected to get approval for production of Viagra generics probably this month or later,” an official in charge of medicine tests told AFP on condition of anonymity. “Our move has nothing to do with an ongoing patent row,” he said, adding the watchdog is also expected to give the go ahead for more local firms.
